Cargando…

Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer

While adjuvant treatment with the selective-estrogen receptor modulator (SERM) tamoxifen has been the standard of care for pre-menopausal patients with hormone receptor (HR) positive breast cancer, recent trials showed a benefit of aromatase inhibitors (AI) and ovarian function suppression (OFS) for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Record, Helena, Clelland, Elle, Rothschild, Harriet T., Kaur, Mandeep, Chien, A. Jo, Melisko, Michelle, Rugo, Hope S., Mujir, Firdows, Huppert, Laura, Mukhtar, Rita A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603127/ https://www.ncbi.nlm.nih.gov/pubmed/37884561 http://dx.doi.org/10.1038/s41523-023-00594-3

Ejemplares similares

Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment
por: Ramalingam, Kirithiga, et al.
Publicado: (2023)

Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy
por: Rothschild, Harriet T., et al.
Publicado: (2023)

Area Deprivation Index in Patients with Invasive Lobular Carcinoma of the Breast: Associations with Tumor Characteristics and Outcomes
por: Kaur, Mandeep, et al.
Publicado: (2023)

HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series
por: Rothschild, Harriet T., et al.
Publicado: (2023)

Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes
por: Clelland, Elle N., et al.
Publicado: (2023)

The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study
por: Abel, Mary Kathryn, et al.
Publicado: (2022)

Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer
por: Rothschild, Harriet T., et al.
Publicado: (2021)

The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database
por: Rothschild, Harriet T, et al.
Publicado: (2023)

Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
por: Abel, Mary Kathryn, et al.
Publicado: (2021)

Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment
por: Lorizio, Wendy, et al.
Publicado: (2011)

Precautions for Patients Taking Tamoxifen or Aromatase Inhibitors
por: Heery, Mary
Publicado: (2023)

Aromatase inhibitors in post-menopausal endometriosis
por: Polyzos, Nikolaos P, et al.
Publicado: (2011)

Cutaneous sarcoidosis possibly associated with aromatase inhibitors and tamoxifen
por: Sawada, Tomoya, et al.
Publicado: (2023)

Amelioration of sexual adverse effects in the early breast cancer patient
por: Melisko, Michelle E., et al.
Publicado: (2010)

Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer
por: Haque, Reina, et al.
Publicado: (2012)

53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease progression – CORRIGENDUM
por: Rothschild, Harriet T, et al.
Publicado: (2023)

The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study
por: Abel, Mary Kathryn, et al.
Publicado: (2021)

Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?
por: Cuzick, J, et al.
Publicado: (2006)

Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
por: Dackus, Gwen M H E, et al.
Publicado: (2021)

Differential impact of tamoxifen and aromatase inhibitors on thrombin generation: the prospective HEMOBREAST cohort
por: Blondon, Marc, et al.
Publicado: (2022)

53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease progression
por: Rothschild, Harriet, et al.
Publicado: (2023)

Uterine metastasis of lobular breast carcinoma under tamoxifen therapy: A case report
por: Awazu, Yuichiro, et al.
Publicado: (2021)

Emerging treatment strategies for metastatic triple-negative breast cancer
por: Huppert, Laura A., et al.
Publicado: (2022)

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
por: Munster, P N, et al.
Publicado: (2011)

Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2023)

Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice
por: Brufsky, Adam, et al.
Publicado: (2023)

Factors related to the experience of menopausal symptoms in women prescribed tamoxifen
por: Moon, Zoe, et al.
Publicado: (2017)

Aromatase inhibitors and their future role in post-menopausal women with early breast cancer.
por: Lønning, P. E.
Publicado: (1998)

Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors
por: Hong, Dongsheng, et al.
Publicado: (2017)

Stick or switch? Audit of the use of switch therapy from tamoxifen to an aromatase inhibitor in breast cancer
por: Weeraman, S, et al.
Publicado: (2010)

Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer
por: Huiart, L, et al.
Publicado: (2011)

Persistence with tamoxifen and aromatase inhibitors in Germany: a retrospective cohort study with 284,383 patients
por: Gremke, Niklas, et al.
Publicado: (2022)

Lobular breast carcinoma metastatic to the endometrium in a patient under tamoxifen therapy: A case report
por: Gomez, Mariangela, et al.
Publicado: (2020)

The role of AKR1 family in tamoxifen resistant invasive lobular breast cancer based on data mining
por: Xu, Dong, et al.
Publicado: (2021)

Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions
por: Harrigan, Maura, et al.
Publicado: (2021)

The role of percutaneous vertebral augmentation in patients with metastatic breast cancer: Literature review including report of two cases
por: Gumusay, Ozge, et al.
Publicado: (2022)

Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older
por: Brufsky, Adam, et al.
Publicado: (2023)

Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration
por: Nagao, Taeko, et al.
Publicado: (2009)

Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.
por: PyrhÃ¶nen, S., et al.
Publicado: (1997)

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer
por: Dowsett, M, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_d8h7s63qbev35qju8p4d0jlucl